Skip to main content
Erschienen in: Drugs & Aging 1/2024

20.11.2023 | Original Research Article

Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial

verfasst von: Cynthia M. Boyd, Susan M. Shetterly, John D. Powers, Linda A. Weffald, Ariel R. Green, Orla C. Sheehan, Emily Reeve, Melanie L. Drace, Jonathan D. Norton, Mahesh Maiyani, Kathy S. Gleason, Jennifer K. Sawyer, Matthew L. Maciejewski, Jennifer L. Wolff, Courtney Kraus, Elizabeth A. Bayliss

Erschienen in: Drugs & Aging | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Patients, family members, and clinicians express concerns about potential adverse drug withdrawal events (ADWEs) following medication discontinuation or fears of upsetting a stable medical equilibrium as key barriers to deprescribing. Currently, there are limited methods to pragmatically assess the safety of deprescribing and ascertain ADWEs. We report the methods and results of safety monitoring for the OPTIMIZE trial of deprescribing education for patients, family members, and clinicians.

Methods

This was a pragmatic cluster randomized trial with multivariable Poisson regression comparing outcome rates between study arms. We conducted clinical record review and adjudication of sampled records to assess potential causal relationships between medication discontinuation and outcomes. This study included adults aged 65+ with dementia or mild cognitive impairment, one or more additional chronic conditions, and prescribed 5+ chronic medications. The intervention included an educational brochure on deprescribing that was mailed to patients prior to primary care visits, a clinician notification about individual brochure mailings, and an educational tip sheets was provided monthly to primary care clinicians. The outcomes of the safety monitoring were rates of hospitalizations and mortality during the 4 months following brochure mailings and results of record review and adjudication. The adjudication process was conducted throughout the trial and included classifications: likely, possibly, and unlikely.

Results

There was a total of 3012 (1433 intervention and 1579 control) participants. There were 420 total hospitalizations involving 269 (18.8%) people in the intervention versus 517 total hospitalizations involving 317 (20.1%) people in the control groups. Adjusted risk ratios comparing intervention to control groups were 0.92 [95% confidence interval (CI) 0.72, 1.16] for hospitalization and 1.19 (95% CI 0.67, 2.11) for mortality. Both groups had zero deaths “likely” attributed to a medication change prior to the event. A total of 3 out of 30 (10%) intervention group hospitalizations and 7 out of 35 (20%) control group hospitalizations were considered “likely” due to a medication change.

Conclusions

Population-based deprescribing education is safe in the older adult population with cognitive impairment in our study. Pragmatic methods for safety monitoring are needed to further inform deprescribing interventions.

Trial Registration

NCT03984396. Registered on 13 June 2019
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945–8.CrossRefPubMed Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc. 1997;45(8):945–8.CrossRefPubMed
4.
Zurück zum Zitat Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.CrossRefPubMed Oscanoa TJ, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly A meta-analysis. Eur J Clin Pharmacol. 2017;73:759–70.CrossRefPubMed
5.
Zurück zum Zitat Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7–8):1017–25.CrossRefPubMed Kongkaew C, Noyce PR, Ashcroft DM. Hospital admissions associated with adverse drug reactions: a systematic review of prospective observational studies. Ann Pharmacother. 2008;42(7–8):1017–25.CrossRefPubMed
8.
Zurück zum Zitat Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.CrossRefPubMedPubMedCentral Reeve E, Gnjidic D, Long J, Hilmer S. A systematic review of the emerging definition of ‘deprescribing’with network analysis: implications for future research and clinical practice. Br J Clin Pharmacol. 2015;80(6):1254–68.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O’Donnell L, Hilmer SN. A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf. 2018;17(1):39–49.CrossRefPubMed Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O’Donnell L, Hilmer SN. A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf. 2018;17(1):39–49.CrossRefPubMed
10.
Zurück zum Zitat Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.CrossRefPubMed Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015;175(5):827–34.CrossRefPubMed
11.
Zurück zum Zitat Scott S, Clark A, Farrow C, et al. Deprescribing admission medication at a UK teaching hospital; a report on quantity and nature of activity. Int J Clin Pharm. 2018;40:991–6.CrossRefPubMed Scott S, Clark A, Farrow C, et al. Deprescribing admission medication at a UK teaching hospital; a report on quantity and nature of activity. Int J Clin Pharm. 2018;40:991–6.CrossRefPubMed
13.
Zurück zum Zitat Bayliss EA, Shetterly SM, Drace ML, et al. The OPTIMIZE patient-and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials. 2020;21:1–13.CrossRef Bayliss EA, Shetterly SM, Drace ML, et al. The OPTIMIZE patient-and family-centered, primary care-based deprescribing intervention for older adults with dementia or mild cognitive impairment and multiple chronic conditions: study protocol for a pragmatic cluster randomized controlled trial. Trials. 2020;21:1–13.CrossRef
14.
Zurück zum Zitat Green AR, Boyd CM, Gleason KS, et al. Designing a primary care–based deprescribing intervention for patients with dementia and multiple chronic conditions: a qualitative study. J Gen Intern Med. 2020;35:3556–63.CrossRefPubMedPubMedCentral Green AR, Boyd CM, Gleason KS, et al. Designing a primary care–based deprescribing intervention for patients with dementia and multiple chronic conditions: a qualitative study. J Gen Intern Med. 2020;35:3556–63.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Clyne B, Fitzgerald C, Quinlan A, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc. 2016;64(6):1210–22.CrossRefPubMed Clyne B, Fitzgerald C, Quinlan A, et al. Interventions to address potentially inappropriate prescribing in community-dwelling older adults: a systematic review of randomized controlled trials. J Am Geriatr Soc. 2016;64(6):1210–22.CrossRefPubMed
17.
Zurück zum Zitat Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRefPubMedPubMedCentral Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583–623.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Iyer S, Naganathan V, McLachlan AJ, Le Conteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021–31.CrossRefPubMed Iyer S, Naganathan V, McLachlan AJ, Le Conteur DG. Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging. 2008;25:1021–31.CrossRefPubMed
19.
Zurück zum Zitat Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.CrossRefPubMed Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890–8.CrossRefPubMed
20.
Zurück zum Zitat Ostini R, Jackson C, Hegney D, Tett SE. How is medication prescribing ceased? A systematic review. Med Care. 2011;49:24–36.CrossRefPubMed Ostini R, Jackson C, Hegney D, Tett SE. How is medication prescribing ceased? A systematic review. Med Care. 2011;49:24–36.CrossRefPubMed
21.
Zurück zum Zitat Bayliss EA, Shetterly SM, Drace ML, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. JAMA Intern Med. 2022;182(5):534–42.CrossRefPubMedPubMedCentral Bayliss EA, Shetterly SM, Drace ML, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. JAMA Intern Med. 2022;182(5):534–42.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Bloomfield HE, Greer N, Linsky AM, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35:3323–32.CrossRefPubMedPubMedCentral Bloomfield HE, Greer N, Linsky AM, et al. Deprescribing for community-dwelling older adults: a systematic review and meta-analysis. J Gen Intern Med. 2020;35:3323–32.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SD, Roberts HC. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21:1–16.CrossRef Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SD, Roberts HC. A systematic review of the evidence for deprescribing interventions among older people living with frailty. BMC Geriatr. 2021;21:1–16.CrossRef
24.
Zurück zum Zitat Reeve E, Low L, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc. 2019;67(6):1204–10.CrossRefPubMed Reeve E, Low L, Hilmer SN. Attitudes of older adults and caregivers in Australia toward deprescribing. J Am Geriatr Soc. 2019;67(6):1204–10.CrossRefPubMed
25.
Zurück zum Zitat Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12): e006544.CrossRefPubMedPubMedCentral Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12): e006544.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Reeve E, Denig P, Hilmer SN, Ter Meulen R. The ethics of deprescribing in older adults. J Bioeth Inq. 2016;13:581–90.CrossRefPubMed Reeve E, Denig P, Hilmer SN, Ter Meulen R. The ethics of deprescribing in older adults. J Bioeth Inq. 2016;13:581–90.CrossRefPubMed
27.
Zurück zum Zitat Sheppard JP, Burt J, Lown M, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039–51.CrossRefPubMedPubMedCentral Sheppard JP, Burt J, Lown M, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA. 2020;323(20):2039–51.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56(10):1946–52.CrossRefPubMedPubMedCentral Bain KT, Holmes HM, Beers MH, Maio V, Handler SM, Pauker SG. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc. 2008;56(10):1946–52.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing medications for chronic diseases management in primary care settings: a systematic review of randomized controlled trials. J Am Med Dir Assoc. 2018;19(11):923-935e2.CrossRefPubMed Dills H, Shah K, Messinger-Rapport B, Bradford K, Syed Q. Deprescribing medications for chronic diseases management in primary care settings: a systematic review of randomized controlled trials. J Am Med Dir Assoc. 2018;19(11):923-935e2.CrossRefPubMed
35.
Zurück zum Zitat Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157(19):2205–10.CrossRefPubMed Graves T, Hanlon JT, Schmader KE, et al. Adverse events after discontinuing medications in elderly outpatients. Arch Intern Med. 1997;157(19):2205–10.CrossRefPubMed
38.
Zurück zum Zitat McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study—electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med. 2022;182(3):265–73.CrossRefPubMed McDonald EG, Wu PE, Rashidi B, et al. The MedSafer study—electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Intern Med. 2022;182(3):265–73.CrossRefPubMed
40.
Zurück zum Zitat Bayliss EA, Albers K, Gleason K, et al. Recommendations for outcome measurement for deprescribing intervention studies. J Am Geriatr Soc. 2022;70(9):2487–97.CrossRefPubMedPubMedCentral Bayliss EA, Albers K, Gleason K, et al. Recommendations for outcome measurement for deprescribing intervention studies. J Am Geriatr Soc. 2022;70(9):2487–97.CrossRefPubMedPubMedCentral
41.
Zurück zum Zitat Fick DM, Semla TP, 2019 American Geriatrics Society Beers Criteria® Update Expert Panel, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.CrossRef Fick DM, Semla TP, 2019 American Geriatrics Society Beers Criteria® Update Expert Panel, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674–94.CrossRef
42.
Zurück zum Zitat Maust DT, Strominger J, Kim HM, et al. Prevalence of central nervous system–active polypharmacy among older adults with dementia in the US. JAMA. 2021;325(10):952–61.CrossRefPubMed Maust DT, Strominger J, Kim HM, et al. Prevalence of central nervous system–active polypharmacy among older adults with dementia in the US. JAMA. 2021;325(10):952–61.CrossRefPubMed
Metadaten
Titel
Evaluating the Safety of an Educational Deprescribing Intervention: Lessons from the Optimize Trial
verfasst von
Cynthia M. Boyd
Susan M. Shetterly
John D. Powers
Linda A. Weffald
Ariel R. Green
Orla C. Sheehan
Emily Reeve
Melanie L. Drace
Jonathan D. Norton
Mahesh Maiyani
Kathy S. Gleason
Jennifer K. Sawyer
Matthew L. Maciejewski
Jennifer L. Wolff
Courtney Kraus
Elizabeth A. Bayliss
Publikationsdatum
20.11.2023
Verlag
Springer International Publishing
Erschienen in
Drugs & Aging / Ausgabe 1/2024
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI
https://doi.org/10.1007/s40266-023-01080-y

Weitere Artikel der Ausgabe 1/2024

Drugs & Aging 1/2024 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.